Fibroblast growth factor-23 and interleukin-6 are risk factors for left ventricular hypertrophy in peritoneal dialysis patients.
Liu, Wei-hua; Zhou, Qiao-ling; Ao, Xiang; Yu, Hong-lei; Peng, Wei-sheng; He, Nan.
J Cardiovasc Med (Hagerstown)
; 13(9): 565-9, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22728833
Compromiso cardiovascular en pacientes pediátricos en diálisis peritoneal crónica.
Reappraisal in two European cohorts of the prognostic power of left ventricular mass index in chronic kidney failure.
A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial.
Vascular calcification and left ventricular hypertrophy in hemodialysis patients: interrelationship and clinical impacts.
Relationship between cardiac calcification and left ventricular hypertrophy in patients with chronic kidney disease at hemodialysis initiation.
Eccentric Left Ventricular Hypertrophy and Sudden Death in Patients with End-Stage Kidney Disease.
Patterns of left ventricular hypertrophy in chronic kidney disease: an echocardiographic evaluation.
The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients.
Czynnik wzrostu fibroblastów-23 (FGF-23). Czesc III. Zaleznosci pomiedzy stezeniem FGF-23 a chorobowoscia i smiertelnoscia sercowo-naczyniowa.
The relationship between snoring and left ventricular hypertrophy of China: a cross-sectional study.